Home Proteases Proteasome

Proteasome Inhibitors

Other Proteases Related Inhibitors

HCV Protease HIV Protease Thrombin MMP Cysteine Protease Serine Protease Tyrosinase Glutaminase PAD Neprilysin

Isoform-selective Products

Cat.No. Product Name Information Product Use Citations Product Validations
S2619 MG132 MG132 ((S,R,S)-(-)-MG132, Z-Leu-D-Leu-Leu-al) is a potent proteasome (ChTL, TL, and PGPH) inhibitor. This compound also inhibits calpain (IC50=1.2 μM). It can be used to induce animal models of Parkinson’s disease.
J Proteomics, 2026, 322:105536
Nature, 2025, 10.1038/s41586-025-09709-1
Signal Transduct Target Ther, 2025, 10(1):26
Verified customer review of MG132
S1013 Bortezomib Bortezomib is a potent 20S proteasome inhibitor with Ki of 0.6 nM. It exhibits favorable selectivity towards tumor cells over normal cells. This compound inhibits NF-κB and induces ERK phosphorylation to suppress cathepsin B and inhibit the catalytic process of autophagy in ovarian cancer and other solid tumors.
J Proteomics, 2026, 322:105536
Signal Transduct Target Ther, 2025, 10(1):81
Cell Host Microbe, 2025, 33(4):512-528.e7
Verified customer review of Bortezomib
S2853 PR-171 (Carfilzomib) Carfilzomib (PR-171) is an irreversible proteasome inhibitor with IC50 of <5 nM in ANBL-6 cells, displayed preferential in vitro inhibitory potency against the ChT-L activity in the β5 subunit, but little or no effect on the PGPH and T-L activities. Carfilzomib activates prosurvival autophagy and induces cell apoptosis.
Nat Genet, 2025, 57(10):2468-2481
Nat Commun, 2025, 16(1):765
Acta Biomater, 2025, S1742-7061(25)00677-4
Verified customer review of PR-171 (Carfilzomib)
S2180 MLN2238 (Ixazomib) Ixazomib (MLN2238) inhibits the chymotrypsin-like proteolytic (β5) site of the 20S proteasome with IC50 and Ki of 3.4 nM and 0.93 nM in cell-free assays, respectively, also inhibits the caspase-like (β1) and trypsin-like (β2) proteolytic sites, with IC50 of 31 and 3500 nM. Ixazomib (MLN2238) induces autophagy. Phase 3.
Nat Commun, 2025, 16(1):3138
Cell Rep Med, 2025, S2666-3791(25)00102-8
Biomed Pharmacother, 2025, 184:117878
Verified customer review of MLN2238 (Ixazomib)
S7038 Epoxomicin (BU-4061T) Epoxomicin (BU-4061T, Aids010837) is a selective proteasome inhibitor with anti-inflammatory activity, which primarily inhibits the CH-L activity of the 20S proteasome, while T-L and PGPH catalytic activities are also inhibited at 100- and 1000-fold reduced rate. This compound promotes apoptosis and can be used to induce animal models of Parkinson's Disease.
Autophagy, 2025, 1-21.
Am J Hum Genet, 2025, 112(2):374-393
Acta Neuropathol, 2024, 148(1):14
Verified customer review of Epoxomicin (BU-4061T)
S7172 ONX-0914 (PR-957) ONX-0914 (PR-957) is a potent and selective immunoproteasome inhibitor, and this compound shows minimal cross-reactivity for the constitutive proteasome in a cell-free assay.
Nat Commun, 2025, 16(1):765
Adv Sci (Weinh), 2024, 11(44):e2405318
J Neurochem, 2024, 10.1111/jnc.16165
Verified customer review of ONX-0914 (PR-957)
S7049 Oprozomib Oprozomib is an orally bioavailable inhibitor for CT-L activity of 20S proteasome β5/LMP7 with IC50 of 36 nM/82 nM. Phase 1/2.
Biosci Rep, 2023, 43(1)BSR20222102
Microbiol Spectr, 2023, 11(5):e0190423
Microbiol Spectr, 2023, 10.1128/spectrum.01904-23
Verified customer review of Oprozomib
S1157 Delanzomib Delanzomib is an orally active inhibitor of the chymotrypsin-like activity of proteasome with IC50 of 3.8 nM, with only marginal inhibition of the tryptic and peptidylglutamyl activities of the proteosome. Phase 1/2.
Cell Rep Med, 2025, S2666-3791(25)00102-8
Int J Mol Med, 2025, 55(5)69
J Fungi (Basel), 2022, 8(2)92
Verified customer review of Delanzomib
S2181 Ixazomib Citrate (MLN9708) Analogue Ixazomib Citrate (MLN9708) Analogue is the analogue of Ixazomib Citrate (MLN9708) from WO2016165677A1. Ixazomib Citrate (MLN9708) immediately hydrolyzed to Ixazomib (MLN2238), the biologically active form, on exposure to aqueous solutions or plasma. Ixazomib (MLN2238) inhibits the chymotrypsin-like proteolytic (β5) site of the 20S proteasome with IC50/Ki of 3.4 nM/0.93 nM in cell-free assays, less potent to β1 and little activity to β2. Ixazomib (MLN2238) induces autophagy. Phase 3.
iScience, 2024, 27(10):110862
EMBO J, 2023, 42(17):e111719
iScience, 2023, 26(6):106997
Verified customer review of Ixazomib Citrate (MLN9708) Analogue
S4432 Ixazomib Citrate (MLN9708) Ixazomib Citrate (MLN9708) is a prodrug of Ixazomib (MLN2238), which is a selective, orally bioavailable inhibitor of 20S proteasome that inhibits the chymotrypsin-like proteolytic (β5) site with IC50 of 3.4 nM and Ki of 0.93 nM, respectively. Ixazomib (MLN2238) also inhibits caspase-like (β1) and trypsin-like (β2) proteolytic sites with IC50 of 31 nM and 3500 nM, respectively.
Journal of Experimental & Clinical Cancer Research, 2022, 249
J Exp Clin Cancer Res, 2022, 41(1):249
Cell Death Dis, 2022, 13(3):197

Signaling Pathway Map